search
Back to results

Clinical Trial of the Use of Intraperitoneal Local Anaesthetic

Primary Purpose

Pain, Postoperative

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Nebulised Bupivacaine intraperitoneally
Normal Saline
Injected Bupivacaine intraperitoneally
No Intraperitoneal Therapeutics
Sponsored by
Imperial College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Pain, Nebulisation, Cholecystectomy, Laparoscopic, Bupivacaine, Local Anaesthetic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: All they patients undergoing laparoscopic cholecystectomy will be included. Exclusion Criteria: Patients with local anaesthetic allergy, patients on chronic opiate medication or those with neurological diseases that make pain evaluation unreliable will be excluded.

Sites / Locations

  • St. Mary's Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Sham Comparator

Placebo Comparator

Experimental

Active Comparator

Arm Label

Control

IP Aerosolized Normal Saline

Nebulised Bupivacaine intraperitoneally

Injected Bupivacaine intraperitoneally

Arm Description

No intraperitoneal therapeutics (No nebulised Bupivacaine)

Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)

Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)

Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)

Outcomes

Primary Outcome Measures

Reduction in Postoperative Pain
Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.

Secondary Outcome Measures

Number of Vomiting / Nausea Episodes
Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.
Hours Needed for Safe Mobilization
Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.
Postoperative Morphine Use
The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events

Full Information

First Posted
September 12, 2005
Last Updated
August 12, 2015
Sponsor
Imperial College London
search

1. Study Identification

Unique Protocol Identification Number
NCT00180687
Brief Title
Clinical Trial of the Use of Intraperitoneal Local Anaesthetic
Official Title
Prospective Double Blind Randomized Controlled Trial of the Use of Intraperitoneal Nebulised Local Anaesthetic
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
October 2004 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
September 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Imperial College London

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Patients undergoing keyhole gall bladder removal will be divided into 3 groups, one control, one will have local anaesthetic and the third will have normal saline nebulised into their abdomen before closure of the wounds to reduce postoperative pain. These medications will be given on top of the standard pain management protocol.
Detailed Description
Pain post laparoscopic procedures can be divided into access related, operation site and distension related. The access type can be attenuated by the use of sub dermal infiltration of local anaesthetic and rarely causes significant discomfort. It has been advocated that placement of a peritoneal gas drain significantly reduces postoperative pain particularly referred to the shoulder tip. Realistically, however, if attention is paid to expelling the residual gas at the end of the procedure this complication is rarely problematic. Operative site pain however is more difficult to manage. In limited gynaecological procedures it has been shown that local installation of local anaesthetic decreased the analgesic requirement of patients post operatively. These observations would not be as transferable to more extensive colorectal or solid organ surgery as the amount of local anaesthesia required would be toxic to the patient. Use of the nebuliser, however maybe able to alleviate pain by efficiently using the dosage required. This is a prospective randomised double blind trial. Sixty patients will be allocated randomly between three groups, 20 patients in each group: Control group Nebulised intraperitoneal local anaesthetic (Bupivacaine 0.25%, 3mg/Kg) Nebulised intraperitoneal normal saline Ward staff will be blinded to which group the patients are in. All patients undergoing laparoscopic cholecystectomy who have given written, informed consent are eligible for inclusion. Patients with local anaesthetics allergy and patients whom pain evaluation is considered unreliable due to chronic opiate use or neurological diseases are excluded. No pre-medication is to be given and a standardised anaesthetic technique is to be employed for all patients. Standard 4 ports technique for laparoscopic cholecystectomy will be used with intraperitoneal pressure between 12-14 mmHg. This will be achieved using CO2 as the insufflation gas. The local anaesthetic (approximately 10mls) will be delivered via a fine sterile catheter that will be inserted via the epigastric port under direct vision at the end of the procedure. Afterward the pneumoperitoneum will be deflated and the wound will be closed and subcutaneous local anaesthetic will be injected in and around the wounds. Postoperatively, all the patients will have PCA as the main analgesia supported by NSAIDs unless contraindicated. Patients will eat and drink as desired and drips will be taken as soon as it is safe to do so. Postoperative pain scoring will be stared in recovery and continue on the wards using the visual analogue scale.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative
Keywords
Pain, Nebulisation, Cholecystectomy, Laparoscopic, Bupivacaine, Local Anaesthetic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Sham Comparator
Arm Description
No intraperitoneal therapeutics (No nebulised Bupivacaine)
Arm Title
IP Aerosolized Normal Saline
Arm Type
Placebo Comparator
Arm Description
Intraperitoneal nebulised 10mls. Normal Saline (No nebulised Bupivacaine)
Arm Title
Nebulised Bupivacaine intraperitoneally
Arm Type
Experimental
Arm Description
Intraperitoneal Nebulised 10mls. Bupivacaione (Marcaine)
Arm Title
Injected Bupivacaine intraperitoneally
Arm Type
Active Comparator
Arm Description
Intraperitoeal Injected 10 mls.Bupivacaine (Marcaine) (No nebulised Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Nebulised Bupivacaine intraperitoneally
Other Intervention Name(s)
Marcaine
Intervention Description
Nebulised Marcaine (Bupivacaine)
Intervention Type
Drug
Intervention Name(s)
Normal Saline
Other Intervention Name(s)
0.9 % Normal Saline
Intervention Description
Nebulised Normal Saline
Intervention Type
Drug
Intervention Name(s)
Injected Bupivacaine intraperitoneally
Other Intervention Name(s)
Marcaine
Intervention Description
Injected Marcaine directly into the peritoneal cavity
Intervention Type
Other
Intervention Name(s)
No Intraperitoneal Therapeutics
Intervention Description
No Intraperitoneal Therapeutics given
Primary Outcome Measure Information:
Title
Reduction in Postoperative Pain
Description
Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.
Time Frame
0 hours, 6 hours, 12 hours, 24 hours
Secondary Outcome Measure Information:
Title
Number of Vomiting / Nausea Episodes
Description
Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.
Time Frame
24 hours
Title
Hours Needed for Safe Mobilization
Description
Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.
Time Frame
24 Hours
Title
Postoperative Morphine Use
Description
The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events
Time Frame
24 Hoiurs

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All they patients undergoing laparoscopic cholecystectomy will be included. Exclusion Criteria: Patients with local anaesthetic allergy, patients on chronic opiate medication or those with neurological diseases that make pain evaluation unreliable will be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nawar A Alkhamesi, MD, PhD
Organizational Affiliation
Imperial College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Mary's Hospital
City
London
ZIP/Postal Code
W2 1NY
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
17180268
Citation
Alkhamesi NA, Peck DH, Lomax D, Darzi AW. Intraperitoneal aerosolization of bupivacaine reduces postoperative pain in laparoscopic surgery: a randomized prospective controlled double-blinded clinical trial. Surg Endosc. 2007 Apr;21(4):602-6. doi: 10.1007/s00464-006-9087-6. Epub 2006 Dec 16.
Results Reference
result

Learn more about this trial

Clinical Trial of the Use of Intraperitoneal Local Anaesthetic

We'll reach out to this number within 24 hrs